ArticleOpen forum infectious diseases2019
The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Off-label use of oritavancin: a case series on clinical effectiveness, bed-day savings and cost benefits.JAC-antimicrobial resistance · 2026Article
- Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study.Infectious diseases and therapy · 2026Article
- Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature.Antibiotics (Basel, Switzerland) · 2026Review
- Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use.Drugs in context · 2026Article
- Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.Frontiers in cellular and infection microbiology · 2026Article
- Bacterial and fungal infections in persons who inject drugs.Clinical microbiology reviews · 2025Review
- Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Common Bacterial Infections in Persons Who Inject Drugs.Medicines (Basel, Switzerland) · 2025Review
- Long-Acting Antibiotics: New Opportunities Beyond Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)!Antibiotics (Basel, Switzerland) · 2025Article
- ORItavancin as a therapeutic regimen for Cardiac Implantable Electronic Devices infections with multidrug-resistant Gram-positive cocci (ORI-4-CIEDi) pilot study: rationale and design.Cardiology journal · 2025Article
- Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes.JAC-antimicrobial resistance · 2024Article
- Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection.Pharmaceutics · 2024Article
- Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement.Infectious diseases and therapy · 2024Article
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- Oritavancin as sequential therapy for Gram-positive bloodstream infections.BMC infectious diseases · 2024Article
- Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM).IDCases · 2024Article
- Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods.Journal of mass spectrometry and advances in the clinical lab · 2024Review
- Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.Open forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOritavancin (ORI) is a long-acting lipoglycopeptide indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible Gram-positive (GP) pathogens.
methodsData collected from a retrospective observational program (2014-2017), Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME), describe the utilization, outcomes, and adverse events (AEs) associated with ORI in 440 patients treated at 26 US sites for ABSSSI and other GP infections.
resultsClinical success in evaluable patients receiving at least 1 dose of oritavancin was 88.1% (386/438). In a subgroup of patients who received ORI for skin and soft tissue infections (n = 401) and bacteremia (n = 7), clinical success was achieved in 89.0% and 100%, respectively. A cohort of 32 patients received 2-10 ORI doses separated by no more than 14 days for complicated GP infections. Clinical success was observed in 30 of 32 patients (93.8%), including 10 of 11 (90.9%) patients with bone and joint infections and 7 of 8 (87.5%) patients with osteomyelitis. In the safety evaluable population, the overall rate of AEs was 6.6%.
conclusionsWe describe results from a real-world program that includes the largest multicenter, retrospective, observational study in patients who received at least 1 dose of ORI for the treatment of GP infections. This study confirms that ORI is an effective, well-tolerated antibiotic used in single and multiple doses for the treatment of ABSSSIs and complicated GP infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.